Search PubMed⌕ Search

Biomedical subjects

E Nielsen

Publications and source records attributed to E Nielsen.

At least 109 records · Page 6Linked to original sources
PubMed1975

Alprenolol in angina pectoris. A comparative study of the tablet form and slow-release formulation.

In a double-blind crossover trial in angina pectoris patients, alprenolol in a slow-release formulation (Aptin Durules) was compared with ordinary Aptin tablets. Four hundred mg per day in tablets given four times a day produced the same increase in exercise tolerance five hours after last intake as did an equivalent dose of slow-release formulation given twice per day nine hours after intake. Aptin Durules in double the dosage had a considerably greater effect. An optimal, sustained and antianginal effect of alprenolol is best achieved by giving 400 to 800 mg per day of slow-release formulation with 10 to 12 hours' dosage interval.

Aged↗
PubMed1975

Local muscle blood flow and sustained contractions of human arm and back muscles.

The endurance during sustained contraction of elbow, flexors, elbow extensors, and back extensors was tested in 3 human subjects. The force level used was varied between ca. 15 and ca. 75% of maximal isometric strength (IS). The clearance of 133Xe from contracting muscles was registered during and after the endurance test. In this way it was possible to determine whether muscle blood flow (MBF) was increased or had stopped during the contraction. Experiments with artificial ischaemia of the upper arm together with MBF measurements showed that MBF was of no importance for continuing sustained contractions above a certain force level, which was 50,25, and 40% of IS for elbow flexors, elbow extensors and back extensors, respectively. However, the level, where longer lasting ( greater than 15 min) sustained contraction is possible is directly related to MBF. These levels were 22, 15, and 20% IS for elbow flexors, elbow extensors, and back extensors, respectively.

Adult↗
PubMed1975

Preserved allografts of dilated saphenous vein for vascular access in hemodialysis: an initial experience.

Arteriovenous fistulas constructed from preserved (frozen) allograft veins provided vascular access for maintenance hemodialysis in 14 patients with inadequate vasculature for conventional autogenous fistulas. Electromagnetic flows ranged from 200 to 250 cc/min. Dialysis flow of 200 cc/min were accomplished consistently. The allografts were useable for dialysis much earlier than autogenous A-V fistulas. Arteriography demonstrated a wide vasculature channel very suitable for dialysis needles. Allografts seemed superior to bovine heterografts in both patency and susceptibility to infection. Scanning electron microscopy revealed smoother initimal surfaces if the donor received small amounts of heparin systemically while the veins were being removed. Allograft veins appear to be a useful alternative means of vascular access for hemodialysis.

Arteriovenous Shunt, Surgical↗
PubMed1975

Genetic and physiological studies on the site of action of distamycin A.

Two new genetic loci of Bacillus subtilis are identified by mutations that confer resistance to distamycin A and to other antibacterial agents. The chromosomal region where they map probably contains a cluster of genes whose products are related to membrane structure and function. Some of the biological effects of distamycin A are still in evidence in the resistant mutants indicating that the drug possibly acts at multiple sites. Most biological effects of the drug (including the phenotypic correction of a morphopoietic mutation) are likely to be due to the interaction of distamycin A with membrane (or surface) structures.

Bacillus subtilis↗